Literature DB >> 1774300

Rapid purification of hepatitis B virus DNA from serum.

R Boom1, C J Sol, R Heijtink, P M Wertheim-van Dillen, J van der Noordaa.   

Abstract

We describe two rapid, simple, and reliable procedures for routine purification of hepatitis B virus (HBV) DNA from serum. HBV DNA could be purified from 24 serum samples in 1.5 to 2 h and was recovered in the initial reaction vessel. Both procedures have in common that HBV DNA is complexed with silica particles in the chaotropic agent guanidinium thiocyanate (GuSCN) but differ in lysis conditions and in the conditions used to elute HBV DNA from the silica particles after purification of the silica-DNA complexes. In one procedure (protocol H), serum HBV lysis was mediated by sodium dodecyl sulfate-proteinase treatment and HBV DNA was subsequently complexed with silica particles in the presence of GuSCN. After washing and drying of the silica-DNA complexes, HBV DNA was eluted from the silica particles in a low-salt buffer. In the other procedure (protocol Y*), serum HBV was directly lysed in GuSCN and HBV DNA was simultaneously complexed with silica particles. After washing and drying of the complexes, HBV DNA was eluted by proteinase treatment in low-salt buffer. Omission of proteinase treatment prevented efficient elution, presumably because of copurification of the protein which is covalently bound to the HBV DNA genome. We show, by Southern blot analysis, that HBV DNA could be reproducibly purified from human serum with the same yields by either procedure (30 to 50% relative to a classic procedure) and apparently independent of serum composition. HBV DNA purified by either method was a good substrate in the polymerase chain reaction compared with DNA purified by the classic procedure.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1774300      PMCID: PMC270215          DOI: 10.1128/jcm.29.9.1804-1811.1991

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  45 in total

1.  Rapid and simple method for purification of nucleic acids.

Authors:  R Boom; C J Sol; M M Salimans; C L Jansen; P M Wertheim-van Dillen; J van der Noordaa
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

2.  Rapid purification of ribosomal RNAs from neutral agarose gels.

Authors:  R Boom; C Sol; P Wertheim-van Dillen
Journal:  Nucleic Acids Res       Date:  1990-04-25       Impact factor: 16.971

3.  Molecular hybridization study of plasma hepatitis B virus DNA from different carriers.

Authors:  H J Lin; P C Wu; C L Lai; S Leong
Journal:  J Infect Dis       Date:  1986-12       Impact factor: 5.226

4.  Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen.

Authors:  C Bréchot; F Degos; C Lugassy; V Thiers; S Zafrani; D Franco; H Bismuth; C Trépo; J P Benhamou; J Wands
Journal:  N Engl J Med       Date:  1985-01-31       Impact factor: 91.245

5.  Hepatitis B virus DNA in Dane particles: evidence for the presence of replicative intermediates.

Authors:  J Scotto; M Hadchouel; S Wain-Hobson; P Sonigo; A M Couroucé; P Tiollais; C Bréchot
Journal:  J Infect Dis       Date:  1985-04       Impact factor: 5.226

6.  Quantitative analysis of hepatitis B virus DNA in saliva and semen of chronically infected homosexual men.

Authors:  S A Jenison; S M Lemon; L N Baker; J E Newbold
Journal:  J Infect Dis       Date:  1987-08       Impact factor: 5.226

7.  High-copy-number derivatives of the plasmid cloning vector pBR322.

Authors:  I Boros; G Pósfai; P Venetianer
Journal:  Gene       Date:  1984-10       Impact factor: 3.688

8.  Rapid and sensitive method for the detection of serum hepatitis B virus DNA using the polymerase chain reaction technique.

Authors:  S Kaneko; S M Feinstone; R H Miller
Journal:  J Clin Microbiol       Date:  1989-09       Impact factor: 5.948

9.  Subtype ayw variant of hepatitis B virus. DNA primary structure analysis.

Authors:  V Bichko; P Pushko; D Dreilina; P Pumpen; E Gren
Journal:  FEBS Lett       Date:  1985-06-03       Impact factor: 4.124

10.  Serum hepatitis B viral DNA in HBsAg-positive hepatocellular carcinoma treated with interferon or adriamycin.

Authors:  H J Lin; C L Lai; P C Wu
Journal:  Br J Cancer       Date:  1986-07       Impact factor: 7.640

View more
  28 in total

1.  Development of a real-time quantitative assay for detection of Epstein-Barr virus.

Authors:  H G Niesters; J van Esser; E Fries; K C Wolthers; J Cornelissen; A D Osterhaus
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  The magnetic immuno polymerase chain reaction assay for direct detection of salmonellae in fecal samples.

Authors:  M N Widjojoatmodjo; A C Fluit; R Torensma; G P Verdonk; J Verhoef
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

3.  Extraction of MS2 phage RNA from upper respiratory tract specimens by use of flat glass devices.

Authors:  Oliver Z Nanassy; Paul Haydock; Nicola Beck; Lynn M Barker; Perry Hargrave; Daniel Gestwick; Wesley C Lindsey; Michael W Reed; J Scott Meschke
Journal:  J Clin Microbiol       Date:  2010-12-29       Impact factor: 5.948

Review 4.  Inhibition and facilitation of nucleic acid amplification.

Authors:  I G Wilson
Journal:  Appl Environ Microbiol       Date:  1997-10       Impact factor: 4.792

5.  Efficient extraction of virus DNA by NucliSens Extractor allows sensitive detection of hepatitis B virus by PCR.

Authors:  E Gobbers; T A Oosterlaken; M J van Bussel; R Melsert; A C Kroes; E C Claas
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

6.  Diverse patterns of recognition of hepatitis C virus core and nonstructural antigens by antibodies present in Egyptian cancer patients and blood donors.

Authors:  M A Attia; A R Zekri; J Goudsmit; R Boom; H M Khaled; M T Mansour; F de Wolf; H M el-Din; C J Sol
Journal:  J Clin Microbiol       Date:  1996-11       Impact factor: 5.948

7.  Isolation of human immunodeficiency virus type 1 (HIV-1) RNA from feces by a simple method and difference between HIV-1 subpopulations in feces and serum.

Authors:  L van der Hoek; R Boom; J Goudsmit; F Snijders; C J Sol
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

8.  A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas.

Authors:  Steven Attia; Jill Kolesar; Michelle R Mahoney; Henry C Pitot; Daniel Laheru; James Heun; Wei Huang; Jens Eickhoff; Charles Erlichman; Kyle D Holen
Journal:  Invest New Drugs       Date:  2008-02-16       Impact factor: 3.850

9.  Polymerase chain reaction for detection of herpesvirus simiae (B virus) in clinical specimens.

Authors:  M J Slomka; D W Brown; J P Clewley; A M Bennett; L Harrington; D C Kelly
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

10.  Detection of Mycobacterium tuberculosis in clinical samples by using polymerase chain reaction and a nonradioactive detection system.

Authors:  A H Kolk; A R Schuitema; S Kuijper; J van Leeuwen; P W Hermans; J D van Embden; R A Hartskeerl
Journal:  J Clin Microbiol       Date:  1992-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.